 |
VOLUME 15: 1995-1996
|
|
| |
| |
45. Health Ministry Statement on Israel-U.S. Health Agreement, 14 May
1995.
During a visit to Washington, Health Minister Ephraim Sneh and U.S.
Secretary of Health and Human Services Donna Shalala extended an existing
health agreement by additional five years. The agreement also covered FDA
recognition of clinical tests carried out in Israel and approval of new
Israeli drugs. Text:
Health Minister Ephraim Sneh and U.S. Secretary of Health and Human
Services Donna Shalala, signed a joint cooperation agreement between
the U.S. and Israel in the health field. The agreement, signed over the
weekend, extends a previous agreement by five years. Shalala responded to
Sneh's request for American surplus medical research equipment to be
transferred to Israel. Sneh announced that he hopes the agreement will
save millions of dollars for research institutions in Israel.
Sneh also met with Dr. Kessler, head of the American Food and Drug
Administration and the two reached an agreement to increase joint
cooperation between the Health Ministry and the FDA. Dr. Kessler agreed to
Sneh's request that the FDA recognize clinical experiments undertaken in
Israel. "This declaration, which will be made after a visit in September
by an FDA review delegation in Israel, will encourage foreign companies to
invest in clinical trials in Israel," said Sneh. Minister Sneh and Dr.
Kessler also agreed that the FDA would transfer to the Health Ministry the
experimental and test findings used for approval of new drugs. This
transfer of information will shorten the approval process for new drugs in
Israel. Minister Sneh also asked the FDA head to speed up approval for
Teva's new drug, "Copaxone," which was developed in Israel and is intended
for the treatment of multiple sclerosis.
|
|
| |